Metabolic tumor volume (MTV) as a biomarker in patients with gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): A multicentre study

#4097

Introduction: 18F-FDG PET/CT avidity predicts for higher histological grade and worse prognosis in patients with NEN. However, there is less evidence regarding the role of FDG-avid tumor volume in predicting prognosis.

Aim(s): To determine if metabolic tumor volume (MTV) on FDG PET/CT predicts prognosis in patients with advanced GEPNEN.

Materials and methods: Multicentre retrospective study in patients with advanced GEPNEN who underwent FDG PET/CT in a previously established cohort. Images were acquired across three centres using harmonised protocols, and were contoured and verified at a flat SUV 4 threshold using a semi-automated MIM Software workflow. Primary endpoint: overall survival (OS). Patients were dichotomized into ‘high’ and ‘low’ MTV groups by the median value, with OS of the two resulting cohorts compared by log-rank tests and multivariate analyses.

Conference:

Presenting Author:

Authors: Chan D, Hayes A, Karfis I, Conner A, Mileva M,

Keywords: prognostic biomarker, PET imaging, 18F-FDG, metabolic tumor volume,